These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12657873)

  • 61. [Use of activated recombinant FVII in the control of haemorrhage following trauma].
    Perrier V; Morel N; Bernard JC; Julliac B; Dewitte A; Pouquet O; Sztark F; Dabadie P
    Ann Fr Anesth Reanim; 2006 Sep; 25(9):990-3. PubMed ID: 16926088
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Off-label use of recombinant factor VIIA concentrates after cardiac surgery.
    Despotis G; Avidan M; Lublin DM
    Ann Thorac Surg; 2005 Jul; 80(1):3-5. PubMed ID: 15975330
    [No Abstract]   [Full Text] [Related]  

  • 63. Adjunctive role for recombinant activated factor VII in the treatment of bleeding secondary to a factor V inhibitor.
    William BM
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):327-8. PubMed ID: 18469559
    [No Abstract]   [Full Text] [Related]  

  • 64. [Administration of activated recombinant factor VII (novo seven) for the control of massive bleeding in gynecology].
    Tanchev S; Pandurski F; Georgiev A; Gesheva Iu; Platikanov V; Dinov P
    Akush Ginekol (Sofiia); 2004; 43 Suppl 2():32-5. PubMed ID: 15518274
    [TBL] [Abstract][Full Text] [Related]  

  • 65. The role of recombinant-activated factor VII in bleeding trauma patients.
    Dutton RP; Conti BM
    Curr Opin Anaesthesiol; 2009 Apr; 22(2):299-304. PubMed ID: 19295430
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa.
    Agarwal N; Spahr JE; Rodgers GM
    Blood Coagul Fibrinolysis; 2007 Mar; 18(2):205-7. PubMed ID: 17287641
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Recombinant activated factor VII and the anaesthetist.
    Welsby IJ; Monroe DM; Lawson JH; Hoffmann M
    Anaesthesia; 2005 Dec; 60(12):1203-12. PubMed ID: 16288618
    [TBL] [Abstract][Full Text] [Related]  

  • 68. New anti-thrombotic agents: emphasis on hemorrhagic complications and their management.
    Ng HJ; Crowther MA
    Semin Hematol; 2006 Jan; 43(1 Suppl 1):S77-83. PubMed ID: 16427390
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Change of coagulation after NovoSeven® use for bleeding during cardiac surgery.
    Tomita E; Takase H; Tajima K; Suematsu Y
    Asian Cardiovasc Thorac Ann; 2017 Feb; 25(2):99-104. PubMed ID: 28114794
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Bleeding time and hemostatic agents].
    Roskam J
    Rev Med Liege; 1973 Aug; 28(16):565-8. PubMed ID: 4755005
    [No Abstract]   [Full Text] [Related]  

  • 71. Massive pulmonary embolism after treatment with rFVIIa in a thrombocytopenic patient with acute myelogenous leukemia and intractable bleeding.
    Mantzios G; Tsirigotis P; Pappa V; Spirou K; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Dervenoulas J
    Eur J Haematol; 2007 Feb; 78(2):173-4. PubMed ID: 17313564
    [No Abstract]   [Full Text] [Related]  

  • 72. [Hemorrhagic complications in liver diseases, their causes, prevention and treatment].
    Pavlovskiĭ DP
    Ter Arkh; 1976; 48(9):138-45. PubMed ID: 793077
    [No Abstract]   [Full Text] [Related]  

  • 73. Successful use of activated recombinant factor VII in traumatic liver injuries in children.
    Kulkarni R; Daneshmand A; Guertin S; Fath J; Atwal M; Melvin J; LaFrance S
    J Trauma; 2004 Jun; 56(6):1348-52. PubMed ID: 15211149
    [No Abstract]   [Full Text] [Related]  

  • 74. [Hemostatic drugs in a patient with antiphospholipid syndrome and clinically significant perioperative bleeding].
    Martínez Rodríguez E; Mato M; Otero J; Ferri JR; Gonzálvez A; Torres LM
    Rev Esp Anestesiol Reanim; 2006 Mar; 53(3):195-7. PubMed ID: 16671265
    [No Abstract]   [Full Text] [Related]  

  • 75. Use of recombinant factor VIIa in a preterm infant with coagulopathy and subdural hematoma.
    Altuncu E; Berrak S; Bilgen H; Yurdakul Z; Canpolat C; Ozek E
    J Matern Fetal Neonatal Med; 2007 Aug; 20(8):627-9. PubMed ID: 17674281
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Recombinant activated factor VII to control bleeding in cardiovascular surgery: need of efficacy and safety validation].
    Blanloeil Y; Rigal JC; Bastien O; Carteau JP; Toussaint-Hacquard M; Lecompte T
    Ann Fr Anesth Reanim; 2006 Jan; 25(1):2-5. PubMed ID: 16377121
    [No Abstract]   [Full Text] [Related]  

  • 77. [Clinical studies in therapy using coagulation-active plasma concentrates].
    Perlick E
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1970; 93(3):300-15. PubMed ID: 4195274
    [No Abstract]   [Full Text] [Related]  

  • 78. Recombinant activated factor VII administration after pulmonary embolectomy: case report.
    Omran N; Harrer J; Brtko M; Habal P; Turek Z; Pojar M; Brozik J
    Heart Surg Forum; 2013 Aug; 16(4):E205-7. PubMed ID: 23958532
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [A 'blind' transfusion policy in patients with acute severe blood loss].
    Frölke JP; Kamphuisen PW; Geeraedts LM; Eijk RJ; Verwiel JM; Kaasjager HA
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1901-6. PubMed ID: 15495986
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Aprotinin in the management of coagulopathy associated with amniotic fluid embolus.
    Stroup J; Haraway D; Beal JM
    Pharmacotherapy; 2006 May; 26(5):689-93. PubMed ID: 16715609
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.